Cumulative Effects of Vicadrostat and Empagliflozin on Albuminuria in CKD
Abstract
Aldosterone excess may lead to accelerated chronic kidney disease (CKD) progression, elevated blood pressure (BP), and an increased risk of cardiovascular events.1,2 The mechanisms of kidney and cardiovascular injury by aldosterone include fibrosis, inflammation, and dysfunctional remodeling.3 Renin-angiotensin system (RAS) inhibitors and nonsteroidal mineralocorticoid receptor antagonists are beneficial for treatment of CKD but may not fully block harmful effects of aldosterone. This may be achieved by targeting aldosterone synthase (AS; CYP11B2), the enzyme that mediates the final steps in aldosterone synthesis.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.